Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility of a randomized, double blind, placebo
controlled trial of add-on rituximab for non-splenectomized adults with acute immune
thrombocytopenic purpura (ITP).